CA2472485A1 - Methode de stimulation des sinus veneux duraux et dure-mere adjacente destinee au traitement d'etats pathologiques - Google Patents
Methode de stimulation des sinus veneux duraux et dure-mere adjacente destinee au traitement d'etats pathologiques Download PDFInfo
- Publication number
- CA2472485A1 CA2472485A1 CA002472485A CA2472485A CA2472485A1 CA 2472485 A1 CA2472485 A1 CA 2472485A1 CA 002472485 A CA002472485 A CA 002472485A CA 2472485 A CA2472485 A CA 2472485A CA 2472485 A1 CA2472485 A1 CA 2472485A1
- Authority
- CA
- Canada
- Prior art keywords
- sinus
- electrode
- disorders
- pain
- medical conditions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 95
- 241001269524 Dura Species 0.000 title claims description 25
- 230000000638 stimulation Effects 0.000 title description 37
- 238000011282 treatment Methods 0.000 title description 12
- 238000002513 implantation Methods 0.000 claims abstract description 59
- 208000002193 Pain Diseases 0.000 claims description 50
- 230000036407 pain Effects 0.000 claims description 49
- 208000019695 Migraine disease Diseases 0.000 claims description 43
- 206010019233 Headaches Diseases 0.000 claims description 39
- 231100000869 headache Toxicity 0.000 claims description 36
- 208000006561 Cluster Headache Diseases 0.000 claims description 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 26
- 208000004296 neuralgia Diseases 0.000 claims description 26
- 210000000798 superior sagittal sinus Anatomy 0.000 claims description 26
- 229940079593 drug Drugs 0.000 claims description 24
- 239000003814 drug Substances 0.000 claims description 24
- 208000035475 disorder Diseases 0.000 claims description 22
- 210000003128 head Anatomy 0.000 claims description 19
- 238000007428 craniotomy Methods 0.000 claims description 14
- 206010027599 migraine Diseases 0.000 claims description 14
- 230000002567 autonomic effect Effects 0.000 claims description 13
- 206010015037 epilepsy Diseases 0.000 claims description 13
- 206010027603 Migraine headaches Diseases 0.000 claims description 12
- 210000001782 transverse sinus Anatomy 0.000 claims description 11
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 10
- 230000002159 abnormal effect Effects 0.000 claims description 9
- 230000001684 chronic effect Effects 0.000 claims description 9
- 208000016285 Movement disease Diseases 0.000 claims description 8
- 206010028836 Neck pain Diseases 0.000 claims description 8
- 230000002503 metabolic effect Effects 0.000 claims description 8
- 230000003387 muscular Effects 0.000 claims description 8
- 210000003625 skull Anatomy 0.000 claims description 8
- 208000019116 sleep disease Diseases 0.000 claims description 8
- 230000000202 analgesic effect Effects 0.000 claims description 7
- 208000026533 urinary bladder disease Diseases 0.000 claims description 7
- KRQUFUKTQHISJB-YYADALCUSA-N 2-[(E)-N-[2-(4-chlorophenoxy)propoxy]-C-propylcarbonimidoyl]-3-hydroxy-5-(thian-3-yl)cyclohex-2-en-1-one Chemical compound CCC\C(=N/OCC(C)OC1=CC=C(Cl)C=C1)C1=C(O)CC(CC1=O)C1CCCSC1 KRQUFUKTQHISJB-YYADALCUSA-N 0.000 claims description 6
- 206010003791 Aura Diseases 0.000 claims description 6
- 208000023275 Autoimmune disease Diseases 0.000 claims description 6
- 206010051550 Carotidynia Diseases 0.000 claims description 6
- 208000006011 Stroke Diseases 0.000 claims description 6
- 206010043269 Tension headache Diseases 0.000 claims description 6
- 208000008548 Tension-Type Headache Diseases 0.000 claims description 6
- 208000018912 cluster headache syndrome Diseases 0.000 claims description 6
- 206010044652 trigeminal neuralgia Diseases 0.000 claims description 6
- 208000003098 Ganglion Cysts Diseases 0.000 claims description 5
- 206010028813 Nausea Diseases 0.000 claims description 5
- 208000005400 Synovial Cyst Diseases 0.000 claims description 5
- 206010047700 Vomiting Diseases 0.000 claims description 5
- 230000004913 activation Effects 0.000 claims description 5
- 230000001667 episodic effect Effects 0.000 claims description 5
- 230000008693 nausea Effects 0.000 claims description 5
- 208000001387 Causalgia Diseases 0.000 claims description 4
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 4
- 208000000060 Migraine with aura Diseases 0.000 claims description 4
- 230000000747 cardiac effect Effects 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 230000008673 vomiting Effects 0.000 claims description 4
- 206010000087 Abdominal pain upper Diseases 0.000 claims description 3
- 206010002329 Aneurysm Diseases 0.000 claims description 3
- 206010059245 Angiopathy Diseases 0.000 claims description 3
- 201000001320 Atherosclerosis Diseases 0.000 claims description 3
- 206010003805 Autism Diseases 0.000 claims description 3
- 208000020706 Autistic disease Diseases 0.000 claims description 3
- 208000020925 Bipolar disease Diseases 0.000 claims description 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 3
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims description 3
- 208000031108 Chronic hiccup Diseases 0.000 claims description 3
- 206010009094 Chronic paroxysmal hemicrania Diseases 0.000 claims description 3
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 claims description 3
- 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 claims description 3
- 208000032106 Complicated migraine Diseases 0.000 claims description 3
- 206010012735 Diarrhoea Diseases 0.000 claims description 3
- 208000014094 Dystonic disease Diseases 0.000 claims description 3
- 208000019530 Eagle syndrome Diseases 0.000 claims description 3
- 206010014020 Ear pain Diseases 0.000 claims description 3
- 206010016059 Facial pain Diseases 0.000 claims description 3
- 208000010541 Familial or sporadic hemiplegic migraine Diseases 0.000 claims description 3
- 208000017228 Gastrointestinal motility disease Diseases 0.000 claims description 3
- 208000003078 Generalized Epilepsy Diseases 0.000 claims description 3
- 208000005922 Glossalgia Diseases 0.000 claims description 3
- 208000004095 Hemifacial Spasm Diseases 0.000 claims description 3
- 206010019476 Hemiplegic migraine Diseases 0.000 claims description 3
- 206010020772 Hypertension Diseases 0.000 claims description 3
- 206010020850 Hyperthyroidism Diseases 0.000 claims description 3
- 208000018127 Idiopathic intracranial hypertension Diseases 0.000 claims description 3
- 206010023848 Laryngeal pain Diseases 0.000 claims description 3
- 208000000112 Myalgia Diseases 0.000 claims description 3
- 208000030858 Myofascial Pain Syndromes Diseases 0.000 claims description 3
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 3
- 208000001132 Osteoporosis Diseases 0.000 claims description 3
- 206010033799 Paralysis Diseases 0.000 claims description 3
- 208000006199 Parasomnias Diseases 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 208000037158 Partial Epilepsies Diseases 0.000 claims description 3
- 208000005538 Post-Dural Puncture Headache Diseases 0.000 claims description 3
- 206010036313 Post-traumatic headache Diseases 0.000 claims description 3
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims description 3
- 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 claims description 3
- 208000036071 Rhinorrhea Diseases 0.000 claims description 3
- 206010039101 Rhinorrhoea Diseases 0.000 claims description 3
- 208000008765 Sciatica Diseases 0.000 claims description 3
- 208000017143 Secondary Headache disease Diseases 0.000 claims description 3
- 208000028347 Sinus disease Diseases 0.000 claims description 3
- 208000005392 Spasm Diseases 0.000 claims description 3
- 208000028911 Temporomandibular Joint disease Diseases 0.000 claims description 3
- 206010043220 Temporomandibular joint syndrome Diseases 0.000 claims description 3
- 206010003119 arrhythmia Diseases 0.000 claims description 3
- 206010003246 arthritis Diseases 0.000 claims description 3
- 210000001326 carotid sinus Anatomy 0.000 claims description 3
- 206010008129 cerebral palsy Diseases 0.000 claims description 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 3
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 claims description 3
- 208000010118 dystonia Diseases 0.000 claims description 3
- 210000000959 ear middle Anatomy 0.000 claims description 3
- 208000007176 earache Diseases 0.000 claims description 3
- 201000006517 essential tremor Diseases 0.000 claims description 3
- 210000004211 gastric acid Anatomy 0.000 claims description 3
- 206010018388 glossodynia Diseases 0.000 claims description 3
- 208000020727 hemicrania continua Diseases 0.000 claims description 3
- 208000003532 hypothyroidism Diseases 0.000 claims description 3
- 230000002989 hypothyroidism Effects 0.000 claims description 3
- 230000003902 lesion Effects 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 201000006938 muscular dystrophy Diseases 0.000 claims description 3
- 210000004237 neck muscle Anatomy 0.000 claims description 3
- 208000007777 paroxysmal Hemicrania Diseases 0.000 claims description 3
- 208000030062 persistent idiopathic facial pain Diseases 0.000 claims description 3
- 208000022821 personality disease Diseases 0.000 claims description 3
- 208000001381 pseudotumor cerebri Diseases 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 210000002345 respiratory system Anatomy 0.000 claims description 3
- 201000000980 schizophrenia Diseases 0.000 claims description 3
- 201000002859 sleep apnea Diseases 0.000 claims description 3
- 230000001148 spastic effect Effects 0.000 claims description 3
- 210000003932 urinary bladder Anatomy 0.000 claims description 3
- 208000019553 vascular disease Diseases 0.000 claims description 3
- 230000003213 activating effect Effects 0.000 claims 2
- 230000001629 suppression Effects 0.000 abstract description 3
- 238000012360 testing method Methods 0.000 description 12
- 210000000988 bone and bone Anatomy 0.000 description 9
- 210000005036 nerve Anatomy 0.000 description 9
- 238000007920 subcutaneous administration Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 210000004126 nerve fiber Anatomy 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 208000007920 Neurogenic Inflammation Diseases 0.000 description 6
- 230000002757 inflammatory effect Effects 0.000 description 6
- 238000002483 medication Methods 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- 230000004936 stimulating effect Effects 0.000 description 6
- 238000001356 surgical procedure Methods 0.000 description 6
- 238000013459 approach Methods 0.000 description 5
- 239000004033 plastic Substances 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 210000000427 trigeminal ganglion Anatomy 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- 230000003444 anaesthetic effect Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 230000023597 hemostasis Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 210000004761 scalp Anatomy 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 208000001375 Facial Neuralgia Diseases 0.000 description 3
- 206010039897 Sedation Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 210000003195 fascia Anatomy 0.000 description 3
- 210000000609 ganglia Anatomy 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 238000002559 palpation Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000036280 sedation Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000700201 Galea Species 0.000 description 2
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- 206010068106 Occipital neuralgia Diseases 0.000 description 2
- 206010054874 Sphenopalatine neuralgia Diseases 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 238000001467 acupuncture Methods 0.000 description 2
- 230000003466 anti-cipated effect Effects 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 210000000133 brain stem Anatomy 0.000 description 2
- 230000001054 cortical effect Effects 0.000 description 2
- 210000003792 cranial nerve Anatomy 0.000 description 2
- 230000003412 degenerative effect Effects 0.000 description 2
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 229960004704 dihydroergotamine Drugs 0.000 description 2
- HESHRHUZIWVEAJ-JGRZULCMSA-N dihydroergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C3=CC=CC4=NC=C([C]34)C2)C1)C)C1=CC=CC=C1 HESHRHUZIWVEAJ-JGRZULCMSA-N 0.000 description 2
- 238000002224 dissection Methods 0.000 description 2
- 235000012489 doughnuts Nutrition 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 230000003447 ipsilateral effect Effects 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 229960004194 lidocaine Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000000944 nerve tissue Anatomy 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 description 2
- 229960004134 propofol Drugs 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000001932 seasonal effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 2
- 229940084026 sodium valproate Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 210000003901 trigeminal nerve Anatomy 0.000 description 2
- FBOUIAKEJMZPQG-AWNIVKPZSA-N (1E)-1-(2,4-dichlorophenyl)-4,4-dimethyl-2-(1,2,4-triazol-1-yl)pent-1-en-3-ol Chemical compound C1=NC=NN1/C(C(O)C(C)(C)C)=C/C1=CC=C(Cl)C=C1Cl FBOUIAKEJMZPQG-AWNIVKPZSA-N 0.000 description 1
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 1
- LCSKNASZPVZHEG-UHFFFAOYSA-N 3,6-dimethyl-1,4-dioxane-2,5-dione;1,4-dioxane-2,5-dione Chemical group O=C1COC(=O)CO1.CC1OC(=O)C(C)OC1=O LCSKNASZPVZHEG-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 description 1
- 102000004414 Calcitonin Gene-Related Peptide Human genes 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 206010012305 Demyelination Diseases 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- 206010015995 Eyelid ptosis Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 206010023644 Lacrimation increased Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 206010028735 Nasal congestion Diseases 0.000 description 1
- 208000005890 Neuroma Diseases 0.000 description 1
- 101000669494 Pelophylax ridibundus Ranakinin Proteins 0.000 description 1
- 208000006735 Periostitis Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010052784 Retinal migraine Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 102400000096 Substance P Human genes 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 239000012984 antibiotic solution Substances 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- SIEYLFHKZGLBNX-UHFFFAOYSA-N bupivacaine hydrochloride (anhydrous) Chemical compound [Cl-].CCCC[NH+]1CCCCC1C(=O)NC1=C(C)C=CC=C1C SIEYLFHKZGLBNX-UHFFFAOYSA-N 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000009232 chiropractic Methods 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 208000012790 cranial neuralgia Diseases 0.000 description 1
- 238000000315 cryotherapy Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 238000002594 fluoroscopy Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- -1 for example Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 210000001932 glossopharyngeal nerve Anatomy 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000000642 iatrogenic effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000002869 intravenous anesthetic agent Substances 0.000 description 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
- 229960004752 ketorolac Drugs 0.000 description 1
- 230000004317 lacrimation Effects 0.000 description 1
- 208000013469 light sensitivity Diseases 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 229940106885 marcaine Drugs 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 206010052787 migraine without aura Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000005015 neuronal process Effects 0.000 description 1
- 229940075680 nitroglycerin sublingual tablet Drugs 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 210000003460 periosteum Anatomy 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 201000003004 ptosis Diseases 0.000 description 1
- 230000001179 pupillary effect Effects 0.000 description 1
- 238000002673 radiosurgery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 description 1
- 229960003708 sumatriptan Drugs 0.000 description 1
- 239000003356 suture material Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 210000000836 trigeminal nuclei Anatomy 0.000 description 1
- ZISSAWUMDACLOM-UHFFFAOYSA-N triptane Chemical class CC(C)C(C)(C)C ZISSAWUMDACLOM-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000006441 vascular event Effects 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention concerne une méthode permettant de supprimer divers aliments. Ce procédé consiste à positionner au moins une électrode adjacente à un site d'implantation (10, 14, 16, 18, 20, 22 et 24) ou autour dudit site.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/667,868 US6405079B1 (en) | 2000-09-22 | 2000-09-22 | Stimulation method for the dural venous sinuses and adjacent dura for treatment of medical conditions |
| PCT/US2002/000315 WO2003059444A1 (fr) | 2000-09-22 | 2002-01-02 | Methode de stimulation des sinus veneux duraux et dure-mere adjacente destinee au traitement d'etats pathologiques |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2472485A1 true CA2472485A1 (fr) | 2003-07-24 |
Family
ID=32962838
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002472485A Abandoned CA2472485A1 (fr) | 2000-09-22 | 2002-01-02 | Methode de stimulation des sinus veneux duraux et dure-mere adjacente destinee au traitement d'etats pathologiques |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2472485A1 (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8977364B2 (en) | 2012-05-03 | 2015-03-10 | Ioannis Mihail Skaribas | External, head-worn electrical stimulator for treating headache conditions |
-
2002
- 2002-01-02 CA CA002472485A patent/CA2472485A1/fr not_active Abandoned
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8977364B2 (en) | 2012-05-03 | 2015-03-10 | Ioannis Mihail Skaribas | External, head-worn electrical stimulator for treating headache conditions |
| US9421358B2 (en) | 2012-05-03 | 2016-08-23 | Ioannis Mihail Skaribas | External, head-worn electrical stimulator for treating headache conditions |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6405079B1 (en) | Stimulation method for the dural venous sinuses and adjacent dura for treatment of medical conditions | |
| US6526318B1 (en) | Stimulation method for the sphenopalatine ganglia, sphenopalatine nerve, or vidian nerve for treatment of medical conditions | |
| US9409022B2 (en) | Methods and systems for stimulating a motor cortex of the brain to treat a medical condition | |
| US6735475B1 (en) | Fully implantable miniature neurostimulator for stimulation as a therapy for headache and/or facial pain | |
| CA2704564C (fr) | Traitements neuraux multi-frequence et systemes et methodes connexes | |
| US7013177B1 (en) | Treatment of pain by brain stimulation | |
| US7684858B2 (en) | Methods and systems for placing an implanted stimulator for stimulating tissue | |
| US9604057B2 (en) | Stimulation method for a sphenopalatine ganglion, sphenopalatine nerve, vidian nerve, or branch thereof for treatment of medical conditions | |
| AU2021202187B2 (en) | Multi-frequency neural treatments and associated systems and methods | |
| CA2472485A1 (fr) | Methode de stimulation des sinus veneux duraux et dure-mere adjacente destinee au traitement d'etats pathologiques | |
| AU2023248130A1 (en) | Multi-frequency neural treatments and associated systems and methods | |
| AU2002303076A1 (en) | Stimulation method for the dural venous sinuses and adjacent dura for treatment of medical conditions | |
| Vajramani | Percutaneous electrical nerve stimulation for facial pain | |
| Salkim et al. | Neuromodulators for Primary Headache Disorders: A Review | |
| Roychoudhury et al. | Complications of Peripheral and Field Stimulation | |
| Streltov et al. | Use of high performance technologies in the treatment of chronic neuropathic pain | |
| Alexander et al. | Spinal cord stimulation for treatment of advanced Parkinson disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |